Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+1-416-5950627
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/10/2019 (Estimated)
OptionableOptionable
Trillium Therapeutics (TSE:TR) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (TSE:TR) issued its earnings results on Monday, March, 11th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.31. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Trillium Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics.
Has Trillium Therapeutics been receiving favorable news coverage?
News coverage about TR stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
What other stocks do shareholders of Trillium Therapeutics own?
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 59)
- Henry Friesen M.D., Independent Director (Age 79)
How do I buy shares of Trillium Therapeutics?
Shares of TR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' official website?
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TSE TR)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TR will underperform the S&P 500 over the long term. You may vote once every thirty days.
